NewsBenzingaMirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints Benzinga 2026.10.12 12:05 (GMT+0) Open on Benzinga Other news Why Is QuantumScape (QS) Stock Trending After Hours US SOL Spot ETF Sees Single-Day Net Outflow of $9.8179 Million HighPeak Energy Stock: Debt Refinancing Reduce Interest Cost More Flexibility (NASDAQ:HPK) Nordson Stock: The Packaging Recovery Is Real, But So Is The Price (NASDAQ:NDSN) What to Expect From Palantir Technologies' Next Quarterly Earnings Report Crypto market rebounds slightly, AI sector up 3.63%, only Meme and CeFi sectors decline
